Professional Documents
Culture Documents
Hypertension and COVID-19: Editorial
Hypertension and COVID-19: Editorial
The world is currently suffering from COVID-19 patients are hypertensive is formation of angiotensin II in the case
the outbreak of a pandemic caused by not entirely surprising nor does it nec- of ACE inhibitors, or by antagonizing
com/apps/opsdashboard/index.html#/ 6. Wan Y, Shang J, Graham R, Baric RS, Li F. 10. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B,
bda7594740fd402994. Accessed 30 March 2020. Receptor recognition by the novel corona- Yang P, Sarao R, Wada T, Leong-Poi H,
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, virus from Wuhan: an analysis based on Crackower MA, Fukamizu A, Hui CC, Hein L,
Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, decade-long structural studies of SARS coro- Uhlig S, Slutsky AS, Jiang C, Penninger JM.
Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, navirus. J Virol 2020; 94:e00127-20. Angiotensin-converting enzyme 2 protects
Cao B. Clinical Course and Risk Factors for 7. Hoffmann M, Kleine-Weber H, Schroeder S, from severe acute lung failure. Nature 2005;
Mortality of Adult Inpatients With COVID- Krüger N, Herrler T, Erichsen S, Schiergens TS, 436:112–116.
19 in Wuhan, China: A Retrospective Cohort Herrler G, Wu N-H, Nitsche A, Müller MA, 11. Phadke M, Saunik S. Rapid response: use
Study. Lancet. 2020; 395:1054–1062. Drosten C, Pöhlmann S. SARS-CoV-2 cell of angiotensin receptor blockers such as
4. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, entry depends on ACE2 and TMPRSS2 and is Telmisartan, Losartsan in nCoV Wuhan
Huang H, Zhang L, Zhou X, Du C, Zhang Y, blocked by a clinically proven protease inhib- Corona Virus infections—novel mode
Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, itor. Cell 2020; 181:1–10. of treatment. Response to the emerging